Medtronic (OBIO) affiliates hold 17.8% of Orchestra BioMed in amended 13G/A

Rhea-AI Filing Summary

Medtronic plc and Covidien Group S. reported shared beneficial ownership of 10,078,625 shares of Orchestra BioMed Holdings, Inc. common stock, representing 17.8%. The calculation is based on 56,464,731 shares outstanding as of November 6, 2025.

The filing is an Amendment No. 3 to a Schedule 13G/A and is signed by authorized representatives with a joint filing agreement in place.

Insights

Corporate Governance Analyst

Medtronic-affiliated entities report a 17.8% stake in Orchestra BioMed.

The excerpt shows shared voting and dispositive power of 10,078,625 shares, with the percentage calculated from 56,464,731 shares outstanding as of November 6, 2025. The filing is an amended Schedule 13G/A and lists a joint filing agreement dated February 6, 2023.

Holder decisions and future disclosures will determine any voting or disposition activity; timing and any planned transactions are not stated in the provided excerpt.

Equity Markets Specialist

A 17.8% position signals meaningful ownership but does not itself imply a change in control.

The filing attributes shared voting and dispositive power to the Medtronic/Covidien entities for 10,078,625 shares. The percentage basis is explicitly tied to the issuer's reported outstanding share count as of November 6, 2025.

Market impact depends on any disclosed sales or purchases in subsequent filings; this amendment documents current beneficial ownership rather than a transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:07 PM Learn about SEC filing dates

FAQ

What stake does Medtronic (OBIO) report in Orchestra BioMed?

Medtronic-affiliated entities report beneficial ownership of 10,078,625 shares, equal to 17.8% of the class. This percentage uses 56,464,731 shares outstanding as of November 6, 2025.

Which entities filed the Schedule 13G/A for OBIO?

The filing is by Medtronic plc and Covidien Group S. and includes a Joint Filing Agreement dated February 6, 2023. Signatures are by authorized representatives dated February 27, 2026.

Does the filing indicate sole voting control of OBIO shares?

No. The excerpt shows 0 shares of sole voting power and 10,078,625 shares of shared voting power, reflecting shared control rather than sole voting authority.

What date is used to calculate the percentage ownership in the filing?

The percentage 17.8% is calculated using the issuer's reported outstanding share count of 56,464,731 as of November 6, 2025, per the issuer's Form 10-Q.

Does this amendment show any purchases or sales of OBIO stock?

This Schedule 13G/A amendment discloses beneficial ownership figures and shared powers; it does not report specific purchases or sales in the provided excerpt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Orchestra BioMed Holdings, Inc.

(Name of Issuer)

Common Stock, Par Value $0.0001 Per Share

(Title of Class of Securities)

68572M106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68572M106

1

Names of Reporting Persons

Medtronic plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

IRELAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 10,078,625.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 10,078,625.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,078,625.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Calculated based on 56,464,731 shares of Common Stock issued and outstanding as of November 6, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed November 10, 2025.

SCHEDULE 13G

CUSIP No. 68572M106

1

Names of Reporting Persons

Covidien Group S.a.r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 10,078,625.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 10,078,625.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,078,625.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Calculated based on 56,464,731 shares of Common Stock issued and outstanding as of November 6, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed November 10, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Orchestra BioMed Holdings, Inc.
(b)	Address of issuer's principal executive offices: 150 UNION SQUARE DRIVE, NEW HOPE, VIRGINIA, 18938.
Item 2.
(a)	Name of person filing: Medtronic plc Covidien Group S.a.r.l.
(b)	Address or principal business office or, if none, residence: Medtronic plc: Building 2, Parkmore Business Park West, Galway, Ireland Covidien Group S.a.r.l., Ground Floor, Espace Monterery, 40 Av Monterey, L-2163 Luxembourg
(c)	Citizenship: Medtronic plc: Ireland Covidien Group S.a.r.l.: Luxembourg
(d)	Title of class of securities: Common Stock, Par Value $0.0001 Per Share
(e)	CUSIP No.: 68572M106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Cover Pages, Items 5 through 11.
(b)	Percent of class:
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote:
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of:
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Medtronic plc

Signature:	/s/ Brian Sandstron
Name/Title:	Assistant Secretary
Date:	02/27/2026

Covidien Group S.a.r.l.

Signature:	/s/ Salvador Sens
Name/Title:	General Manager
Date:	02/27/2026

Exhibit Information

Joint Filing Agreement between Medtronic plc and Covidien Group S.a.r.l., dated as of February 6, 2023, filed as Exhibit 1 to the Schedule 13G filed on February 6, 2023.